Hims & Hers Health, Inc. sees 38% YoY subscriber growth, driven by 70% choosing personalized treatments. Click for my updated ...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock lately despite its ...

Hims & Hers (HIMS) defends recovery with personalized healthcare adoption, GLP-1 partnerships, and profit growth. Click here ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

When it comes to healthcare stocks, many investors pay attention to the usual suspects: Eli Lilly, Novo Nordisk, CVS Health, or Johnson & Johnson. These companies have built up enormous brand equity ...

Hims & Hers (NYSE: HIMS) stock, a prominent player in the booming telehealth sector, has undeniably captured significant investor attention recently. Perhaps you, like many others, have been caught up ...

Ozempic is an FDA-approved medication for people with type 2 diabetes. It’s often prescribed off-label for weight loss — that ...

Hers launched the first-ever prescription-grade gummy for hair loss. Here's what to know and how to get it. Nasha is a Managing Editor for CNET, overseeing our sleep and wellness verticals.

But have you tried a prescription gummy for hair loss? Hers, a telehealth company that provides online healthcare services and products for women, announced the launch of its Biotin plus Minoxidil ...